Compugen (CGEN) Given a $9.00 Price Target at Oppenheimer

Oppenheimer set a $9.00 price objective on Compugen (NASDAQ:CGEN) in a report published on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, Zacks Investment Research upgraded shares of Compugen from a sell rating to a hold rating in a research report on Monday, July 16th.

Shares of CGEN traded down $0.06 during mid-day trading on Wednesday, reaching $3.33. The stock had a trading volume of 110,037 shares, compared to its average volume of 419,679. The firm has a market cap of $180.55 million, a P/E ratio of -4.63 and a beta of 1.32. Compugen has a 12 month low of $2.25 and a 12 month high of $5.00.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings results on Wednesday, November 7th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.12) by $0.07. The firm had revenue of $7.80 million during the quarter, compared to the consensus estimate of $7.80 million. Equities research analysts expect that Compugen will post -0.42 EPS for the current year.

Several institutional investors and hedge funds have recently bought and sold shares of CGEN. Commonwealth Equity Services LLC bought a new position in shares of Compugen in the second quarter worth approximately $106,000. Aviance Capital Management LLC bought a new position in shares of Compugen in the third quarter worth approximately $151,000. Benjamin F. Edwards & Company Inc. boosted its position in shares of Compugen by 34.4% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 167,600 shares of the biotechnology company’s stock worth $553,000 after purchasing an additional 42,900 shares during the period. UBS Group AG boosted its position in shares of Compugen by 1,813.2% in the first quarter. UBS Group AG now owns 316,066 shares of the biotechnology company’s stock worth $1,406,000 after purchasing an additional 299,546 shares during the period. Finally, Taylor Frigon Capital Management LLC boosted its position in shares of Compugen by 24.3% in the second quarter. Taylor Frigon Capital Management LLC now owns 666,302 shares of the biotechnology company’s stock worth $2,199,000 after purchasing an additional 130,217 shares during the period. Institutional investors and hedge funds own 20.69% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company's therapeutic pipeline consists of immuno-oncology programs against novel drug targets in the areas of unmet medical needs in various cancer types and patient populations.

Featured Story: Price to Earnings Ratio (PE)

Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit